PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  05/20 04:03:19 pm EDT
52.47 USD   +3.59%
04:31pWall Street ends mixed after punishing week
RE
01:16pRite Aid to Start Administering Pfizer's Booster Shot to Chidren Ages 5 to 11
MT
11:07aPfizer Enters Deal to Sell COVID-19 Drug Paxlovid to Switzerland
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT

01/16/2022 | 04:33pm EDT

GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT


© Reuters 2022
All news about PFIZER, INC.
04:31pWall Street ends mixed after punishing week
RE
01:16pRite Aid to Start Administering Pfizer's Booster Shot to Chidren Ages 5 to 11
MT
11:07aPfizer Enters Deal to Sell COVID-19 Drug Paxlovid to Switzerland
MT
10:54aPfizer's Xeljanz Recommended By European Medicines Agency Committee to Treat Ankylosing..
MT
09:39aSwitzerland Secures Order for Pfizer's Antiviral COVID-19 Drug Paxlovid
MT
06:28aEU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema..
MT
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
MT
05/19CDC urges Pfizer booster for children ages 5 to 11
AQ
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/19Thinking about trading options or stock in Tesla, Microsoft, Walt Disney, NVIDIA, or Pf..
PR
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,45x
Yield 2022 3,20%
Capitalization 294 B 294 B -
EV / Sales 2022 2,73x
EV / Sales 2023 3,58x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 50,65 $
Average target price 57,79 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-11.14%284 192
JOHNSON & JOHNSON2.59%457 706
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689
NOVO NORDISK A/S-0.56%236 239